Blogging the biotechnology revolution

Systems Biology is changing the way biology is done. Is it a fad or is it effective? This blog tracks current happenings and helps you stay on top of the field. You can find a list of relevant papers at systems biology paper watch Have you heard a talk or read a paper in bioinformatics / systems biology you would like to tell other people about? Email: bioinfblog@gmail.com and get the word out!

Saturday, December 03, 2005

Keith Elliston, Genestruct
"What is the significance of Systems Biology and Regulatory Genomics to industry?"
Its clear from vioxx etc that drug companies dont know the molecular action of their drugs, this is where sys biology can help
There is a 'cognitive barrier' that so much is known that people cant get their head around it. SYstems biology is to filter al that is known to 'actionable' items that can be directly addressed.

For drug companies, novel target identification is the hardest task, but the least interesting for drug companies. It takes between 800 million and a billion dollars to make a blockbuster drug. So have to recoup costs before patent runs out..

Agrees with Lee Hood that SBs biggest effect is on biomarkers (personalized medicine). There is some talk that companies are afraid of personalized medicine because it lowers their revenue since they would get the right drug the first time. This was confirmed to some extent, that only the really visionary companies will support this. This will need a change in paradigm at the FDA since drugs will work great for a small percentage of the population and will get rejected even though they are more appropriate for that small fraction.

3 Comments:

Anonymous Anonymous said...

It is interesting to see myself quoted on this blog. But, to correct things in retrospect... I do think that Biomarkers will be the first key application of systems biology, and Genstruct is leading the way here. We have numerous biomarkers in validation with our partners (which include Pfizer and GSK) and are working on drugs in early to late (as late as phase III) clinical stage drugs. I believe that the pharma industry will embrace personalized medicine, and will rapidly identify new technologies and methodologies to capitalize on personalized medicine to advance drugs in the pipelines. it will, however, require a financial (earlier to market) incentive... but given one or two successes, the wave will build.

Keep up the good work.

Keith

8:19 PM  
Anonymous Elaine said...

I saw really much worthwhile info in this post!

6:00 AM  
Anonymous Anonymous said...

top [url=http://www.c-online-casino.co.uk/]online casino[/url] coincide the latest [url=http://www.realcazinoz.com/]realcazinoz.com[/url] manumitted no consign bonus at the chief [url=http://www.baywatchcasino.com/]easy casino
[/url].

4:04 AM  

Post a Comment

<< Home